Debate – Fixed Duration Versus Until Progression: How Long Should the Initial Treatment of Myeloma Last?
The introduction of new treatment options in multiple myeloma (MM) has led to marked improvements in overall outcomes of patients. Attempts to make further improvements have focused on understanding the biology of MM, finding new treatment options, and on optimizing treatment outcomes with currently available therapies such as various combinations of available drugs and modifying treatment duration. A uniform myeloma treatment approach cannot be applied to all patients as the molecular characteristics of MM vary from one patient to another. Therefore, recognizing the pros and cons of fixed duration versus therapy until progression will help clinicians adapt treatment strategies to match individual patient needs.
This information was originally presented at the NCCN 2019 Annual Congress: Hematologic Malignancies™ held in San Francisco, CA, on September 27-28, 2019.
Target Audience
This educational program is designed to meet the educational needs of the interprofessional oncology care team, including: physicians/oncologists, nurses, physician assistants, pharmacists, and other healthcare professionals who manage patients with cancer.
Learning Objectives
Following this program, participants should be able to:
- Summarize the evidence from recent clinical trials supporting the use of targeted therapy for patients with newly diagnosed chronic lymphocytic leukemia.
- Recognize the emerging role of IGHV mutation status in the selection of first-line therapy, and identify patients with newly diagnosed chronic lymphocytic leukemia who could be candidates for chemoimmunotherapy.
- Develop an individualized treatment plan for patients with newly diagnosed chronic lymphocytic leukemia based on the disease-specific and patient-specific characteristics.
Facilitated by:
Andrew D. Zelenetz, MD, PhD
Memorial Sloan Kettering Cancer Center
Presented by:
Yvonne A. Efebera, MD, MPH
The Ohio State University Comprehensive Cancer Center- James Cancer Hospital and Solove Research Institute
Nina Shah, MD
UCSF Helen Diller Family Comprehensive Cancer Center
Panelists:
Muhamed Baljevic, MD
Fred & Pamela Buffett Cancer Center
Jorge J. Castillo, MD
Dana-Farber Cancer Institute
Michaela Liedtke, MD
Stanford Cancer Institute
NCCN Medical Education Disclosure Policy
It is the policy of NCCN that every 12 months, all faculty, moderators, activity planners and all internal planning staff participating in NCCN continuing education activities are expected to disclose any financial relationships with a commercial interest as defined by the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support. In addition, all faculty presentations have been reviewed for adherence to the ACCME’s Standards for Commercial Support (the provider develops activities/educational interventions independent of commercial interests [SCS 1, 2 and 6] by experts on the topics).
Per the ACCME Standards for Commercial Support, individuals who do not disclose relevant financial relationships will be disqualified from involvement in the CE activity as a content developer, planner, or presenter. A complete list of individuals’ relationships with external entities is available upon request.
Definitions
NCCN continuing education considers financial relationships to create a “conflict of interest” when an individual has both a financial relationship with a commercial interest and the opportunity to affect CE content about the products or services of a commercial interest with which he/she and/or a spouse or partner has a financial relationship.
NCCN continuing education considers “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. NCCN does not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship.
Faculty Disclaimers
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.
Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling.
Faculty Disclosures
The faculty listed below discloses the following relevant financial relationships:
Andrew D. Zelenetz, MD, PhD
AbbVie, Inc.: Consulting Fee; Scientific Advisor
Adaptive Biotechnologies Corporation: Consulting Fee
Amgen Inc.: Consulting Fee
AstraZeneca Pharmaceuticals LP: Consulting Fee; Scientific Advisor
BeiGene: Grant/Research Support; Other Financial Benefit
Celgene Corporation: Consulting Fee
Genentech, Inc./Roche Laboratories, Inc.: Consulting Fee
Gilead Sciences, Inc.: Consulting Fee; Grant/Research Support
Janssen Pharmaceutica Products, LP: Consulting Fee
MEI Pharma Inc.: Grant/Research Support
MorphoSys AG: Scientific Advisor
Novartis Pharmaceuticals Corporation: Consulting Fee
Pharmacyclics: Consulting Fee
Roche Laboratories, Inc.: Grant/Research Support
Yvonne A. Efebera, MD, MPH
Akcea Therapeutics: Scientific Advisor
Janssen Pharmaceutica Products, LP: Honoraria
Takeda Pharmaceuticals North America, Inc.: Honoraria
Muhamed Baljevic, MD
Cardinal Health: Consulting Fee
Karyopharm Therapeutics:Scientific Advisor
Takeda Pharmaceuticals North America, Inc.: Consulting Fee; Scientific Advisor
Jorge J. Castillo, MD
AbbVie, Inc.: Consulting Fee; Grant/Research Support
BeiGene: Consulting Fee; Grant/Research Support
Janssen Pharmaceutica Products, LP: Consulting Fee; Grant/Research Support
Pharmacyclics: Consulting Fee; Grant/Research Support
TG Therapeutics, Inc.: Grant/Research Support
Michaela Liedtke, MD
Agios, Inc.: Grant/Research Support
Amgen Inc.: Grant/Research Support; Consulting Fee
bluebird bio, Inc.: Grant/Research Support
Celator Pharmaceuticals: Grant/Research Support
Celgene Corporation: Grant/Research Support; Scientific Advisor
Genentech, Inc.: Grant/Research Support
Gilead Sciences, Inc.: Grant/Research Support
Janssen Pharmaceutica Products, LP: Grant/Research Support; Scientific Advisor
Jazz Pharmaceuticals Inc.: Scientific Advisor
Pfizer Inc.: Grant/Research Support
Prothena: Grant/Research Support
Takeda Pharmaceuticals North America, Inc.: Grant/Research Support
The faculty listed below discloses no relevant financial relationships:
Nina Shah, MD
NCCN Staff Disclosures
The NCCN Activity Planning staff listed below discloses no relevant financial relationships:
Melissa Esplen; Mark A. Geisler; Kristina M. Gregory, RN, MSN, OCN; Kristin Kline Hasson; Rose Joyce; Karen Kanefield; Lisa Perfidio, MS; Shannon Ryan, CMP; Sarah Sinclair; Kathy Ann Smith, CHCP
The NCCN Leadership listed below discloses no relevant financial relationships:
Robert W. Carlson, MD; Wui-Jin Koh, MD; Gary J. Weyhmuller, MBA, SPHR
The NCCN Clinical staff listed below discloses no relevant financial relationships:
Jennifer Keller; Rashmi Kumar, PhD
In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physicians
NCCN designates this enduring activity for a maximum of .75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses
NCCN designates this educational activity for a maximum of .82 contact hours.
Pharmacists
NCCN designates this knowledge-based continuing education activity for .75 contact hours (0.075 CEUs) of continuing education credit. UAN: JA4008196-0000-19-095-H01-P
Physician Assistants
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Catergory 1 CME credit for activities planned in accordance with AAPA CME criteria. This activity is designated for .75 AAPA Catergory 1 CME credits. Approval is valid until October 31, 2020. PAs should only claim credit commensurate with the extent of their participation.
Available Credit
- 0.75 AAPA Category 1 CME credit
- 0.75 ACPE contact hours
- 0.75 AMA PRA Category 1 Credit™
- 0.82 ANCC contact hours
- 0.75 Participation
Price
Required Hardware/software
To complete this activity, users will need:
- A device with an Internet connection
- One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari (Internet Explorer is no longer supported)
- Adobe Flash Player and/or an HTML5 capable browser for video or audio playback
- Adobe Reader or other PDF reader software for certificate viewing/printing